These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21372110)

  • 1. Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses.
    Montanuy I; Alejo A; Alcami A
    FASEB J; 2011 Jun; 25(6):1960-71. PubMed ID: 21372110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Does Vaccinia Virus Interfere With Interferon?
    Smith GL; Talbot-Cooper C; Lu Y
    Adv Virus Res; 2018; 100():355-378. PubMed ID: 29551142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A virus-encoded type I interferon decoy receptor enables evasion of host immunity through cell-surface binding.
    Hernáez B; Alonso-Lobo JM; Montanuy I; Fischer C; Sauer S; Sigal L; Sevilla N; Alcamí A
    Nat Commun; 2018 Dec; 9(1):5440. PubMed ID: 30575728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evasion of the Innate Immune Type I Interferon System by Monkeypox Virus.
    Arndt WD; Cotsmire S; Trainor K; Harrington H; Hauns K; Kibler KV; Huynh TP; Jacobs BL
    J Virol; 2015 Oct; 89(20):10489-99. PubMed ID: 26246580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of the viral chemokine-binding protein E163 from ectromelia virus.
    Heidarieh H; Alcamí A
    J Biol Chem; 2018 Nov; 293(45):17418-17429. PubMed ID: 30257868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of poxvirus orthologues of the vaccinia virus E3 protein: modulation of protein kinase R activity, cytokine responses, and virus pathogenicity.
    Myskiw C; Arsenio J; Hammett C; van Bruggen R; Deschambault Y; Beausoleil N; Babiuk S; Cao J
    J Virol; 2011 Dec; 85(23):12280-91. PubMed ID: 21917954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.
    Fernández de Marco Mdel M; Alejo A; Hudson P; Damon IK; Alcami A
    FASEB J; 2010 May; 24(5):1479-88. PubMed ID: 20019241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist.
    Soday L; Lu Y; Albarnaz JD; Davies CTR; Antrobus R; Smith GL; Weekes MP
    Cell Rep; 2019 May; 27(6):1920-1933.e7. PubMed ID: 31067474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins.
    Bandi P; Pagliaccetti NE; Robek MD
    J Interferon Cytokine Res; 2010 Mar; 30(3):123-34. PubMed ID: 20038204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulation by proteins secreted from cells infected by vaccinia virus.
    Smith GL; Symons JA; Alcamí A
    Arch Virol Suppl; 1999; 15():111-29. PubMed ID: 10470273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.
    Liszewski MK; Leung MK; Hauhart R; Fang CJ; Bertram P; Atkinson JP
    J Immunol; 2009 Sep; 183(5):3150-9. PubMed ID: 19667083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1.
    Meng X; Schoggins J; Rose L; Cao J; Ploss A; Rice CM; Xiang Y
    J Virol; 2012 Apr; 86(8):4538-47. PubMed ID: 22345458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN.
    Alcamí A; Symons JA; Smith GL
    J Virol; 2000 Dec; 74(23):11230-9. PubMed ID: 11070021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide mimetics of gamma interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein.
    Ahmed CM; Burkhart MA; Subramaniam PS; Mujtaba MG; Johnson HM
    J Virol; 2005 May; 79(9):5632-9. PubMed ID: 15827178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment.
    Liszewski MK; Bertram P; Leung MK; Hauhart R; Zhang L; Atkinson JP
    J Immunol; 2008 Sep; 181(6):4199-207. PubMed ID: 18768877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose.
    Singh K; Gittis AG; Gitti RK; Ostazeski SA; Su HP; Garboczi DN
    J Virol; 2016 May; 90(10):5020-5030. PubMed ID: 26937025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of vaccinia virus E3 protein: the biological functions do not correlate with its biochemical capacity to bind double-stranded RNA.
    Dueck KJ; Hu YS; Chen P; Deschambault Y; Lee J; Varga J; Cao J
    J Virol; 2015 May; 89(10):5382-94. PubMed ID: 25740987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus.
    Huang J; Smirnov SV; Lewis-Antes A; Balan M; Li W; Tang S; Silke GV; Pütz MM; Smith GL; Kotenko SV
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9822-7. PubMed ID: 17517620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain.
    Cao H; Dai P; Wang W; Li H; Yuan J; Wang F; Fang CM; Pitha PM; Liu J; Condit RC; McFadden G; Merghoub T; Houghton AN; Young JW; Shuman S; Deng L
    PLoS One; 2012; 7(5):e36823. PubMed ID: 22606294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.
    Silva LA; Khomandiak S; Ashbrook AW; Weller R; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Mar; 88(5):2385-97. PubMed ID: 24371059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.